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Introduction
Chagas disease (CD) is a highly prevalent
parasitic disease in immigrants from Mex-
ico, as well as all of Central and South
America. The total number of infected
people is estimated between eight and ten
million [1,2], of whom 30%–40% either
have, or will, develop cardiopathy, gastro-
intestinal disease, or both [1]. Cardiac
involvement is the main cause of death
from this infection through arrhythmias
and cardiomyopathy. Nifurtimox and
benznidazole are the only available medi-
cines with proven efficacy against Trypano-
soma cruzi infection in acute, congenital
infection and early chronic infection. Until
recently the treatment of chronic disease,
particularly of adult patients with indeter-
minate form, was controversial; but during
the past decade there has been a trend to
offer treatment to adult patients and those
with early cardiomyopathy [3].
To understand the magnitude of the
problem, some economic studies have
calculated the global cost of the disease
worldwide at around 7,200,000,000 Amer-
ican dollars per year [4], which is mainly due
to cardiovascular disease and early mortal-
ity. This cost is similar to, or even higher
than, other prominent conditions such as
rotavirus disease or cervical cancer [4].
In endemic countries, the main trans-
mission route to humans is vectorial
transmission through the faeces of infected
triatomine bugs [1]. Oral transmission also
occurs in endemic countries when bever-
ages or food are contaminated with triato-
mine faeces [5]. Transmission through
blood transfusion, organ transplantation
from an infected donor, or from mother
to child are less common routes, although
they are of increasing importance, partic-
ularly in nonendemic areas where vectorial
and oral transmission do not occur [1].
Another sporadic route of transmission is
through the syringe sharing among drug
users [6].
During the past decade, the infection has
become a public health problem in some
nonendemic countries, mainly due to
migration and the chronic carriage of T.
cruzi infection among a proportion of
immigrants from endemic Latin American
countries [7]. Since the first report of a case
of CD in Europe was published in 1981 [8],
sporadic cases have been detected in
different European countries [9]. Since
2000, the number of reported cases has
alarmingly increased, particularly in Spain
and, to a lesser extent, in Italy and
Switzerland [9–15].
In Europe, the currently estimated
number of people with CD is between
68,000 and 122,000, but by 2009 only
4,290 had been diagnosed (index of
underdiagnosis 93.9%–96.4%) [16].
The risk of transmission of T. cruzi
infection in nonendemic countries through
blood transfusion and organ transplanta-
tion has been described in multiple studies
in the USA and more recently in Europe
[17–21]. Moreover, several confirmed cas-
es of T. cruzi transmission have already
been detected in Europe [9,22]. Accord-
ingly, some studies have shown that it is
cost-effective to screen for T. cruzi infection
at blood banks, but depending on the
prevalence of the disease, a mass screening
of subjects—testing all—or a more selected
strategy with screening questions to
determine the risk level—screening and
testing—should be applied [23].
Regarding congenital transmission, sev-
eral studies have reported a rate of
seroprevalence in Europe from 1.53% to
9.7% in pregnant women with the Bolivian
population showing the highest seropreva-
lence rate [10,24,25], and with a transmis-
sion rate to newborn of around 7.3% [10].
Moreover, the strategy of screening
pregnant women to control and treat
newly diagnosed infected newborns has
also shown to be cost-effective [26].
In response, several nongovernmental
and later governmental initiatives have
developed strategies to tackle this public
health problem in the last years. The main
aim of these initiatives has been to control
the main transmission routes in nonen-
demic countries. Accordingly, some Euro-
pean countries have implemented national
or regional measures to control transmis-
sion [27,28], but many countries still have
no legislation about it.
In 2009, the World Health Organization
(WHO) convened a WHO informal con-
sultation (jointly organized by WHO head-
quarters and the WHO Regional Office for
Europe) that performed a comprehensive
review outlining this specific issue in
Europe [29]. In collaboration with WHO,
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a research group working on migrant
health, COHEMI, (COordinating resourc-
es to assess and improve HEalth status
of MIgrants from Latin America) has
undertaken this study aimed at reviewing
the health policies implemented in Euro-
pean Union countries with the highest
disease prevalence, plus Switzerland, to
control the transmission of CD through
blood transfusion, organ transplantation,
and the congenital route.
Methods
A comprehensive search was performed
to review health policies to control trans-
mission of CD in different European
countries. We selected countries belonging
to the European Union (EU) before 2004.
Switzerland was also included for the
purpose of this study due to the high
number of at risk immigrants as well as the
increasing number of confirmed cases of
T. cruzi infection in that country [30].
Countries joining the EU after 2004 were
not included because of the low number of
at risk immigrants and scarce or nonexis-
tent data about CD in these countries.
The search strategy, available at http://
www.cohemi-project.eu/Pages/Our_Activities/
Products/Other.aspx, was based on an on-
line search of health policies in blood banks,
transplant, and antenatal care programs. In
addition, a short questionnaire was distrib-
uted among one or two experts in tropical
medicine and international health from 15
European countries (Figure 1). Respondents
were asked to provide information about
existing policies implemented to control CD
transmission in their countries or regions.
They were also asked to provide the contact
details of acting experts of the Ministry of
Health in their countries and in the
European Union as well as from blood
banks, national transplant organizations, and
antenatal care services of different European
countries. When available, these experts
and/or organizations were also contacted
to confirm or to provide some specific
information about a particular country.
The information was validated when the
directive, legislation, protocol, or document
was obtained and accordingly, it was
checked to see if the document contained a
specific mention about how to control T.
cruzi infection. The search was updated in
September 2013. A map illustrating the
measures currently implemented to control
transmission in European countries (blood
banks, organ transplantation, and congenital
transmission) at the national and subnational
levels was built.
Results
A total of 15 questionnaires were
received from 17 experts in 12 European
countries. In addition, 18 blood banks
from 14 countries and nine transplant
organizations from seven EU/European
Economic Area (EEA) countries were
further contacted, and reply was received
from nine blood banks and seven trans-
plant organizations. No data were ob-
tained from three countries (Austria,
Greece, and Ireland). These three coun-
tries are estimated to host a low number of
immigrants at risk and were not consid-
ered further in this study.
The data obtained are shown in Fig-
ures 1, 2, and 3 and summarized in the
following paragraphs.
Blood transfusion health policy
The United Kingdom has implemented
systematic screening of at risk blood
donations for T. cruzi infection since
1999 through professional guidelines is-
sued by the Joint United Kingdom Blood
Transfusion Services Professional Advisory
Committee (JPAC). In Spain and France,
obligatory screening has been implement-
ed since 2005 and 2009 respectively in
those people at risk of infection. Switzer-
Figure 1. Questionnaire on health policy on T. cruzi infection in EU countries.
doi:10.1371/journal.pntd.0003245.g001
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land is the last country to have changed its
directives in this regard (in January 2013)
(Figure 2).
In these four countries, (i) blood donors
born in endemic areas, or (ii) donors born
to mothers native of endemic areas, or (iii)
recipients of blood transfusions in endemic
areas must be tested for T. cruzi infection
before the blood donation. Italy is cur-
rently processing a similar change in the
blood transfusion regulation in order to
test all individuals at risk of T. cruzi
infection, but the measure had not been
officially approved at the time of the last
update of the search strategy. In Portugal,
a blood safety protocol will shortly be
approved by the Instituto Portugueˆs do
Sangue e da Transplantac¸a˜o. Following
this protocol, people at risk for T. cruzi
infection will be directly excluded from
donation. After the approval, a new
directive needs to be implemented. In
Sweden, systematic screening has not been
implemented in blood banks, but all
individuals who lived more than five years
in Chagas disease–endemic countries
(irrespective of whether or not they were
born there) are systematically excluded
from donation.
The other European countries are
currently applying the European Commis-
sion’s directives, 2004/33/CE and 2006/
17/CE, approved by the EU related to
quality and safety of blood, tissue, and cell
donation in blood banks (Table 1). In
these documents, individuals known to be
infected with T. cruzi are specifically
mentioned and defined as an exclusion
criteria for blood donation. However,
these directives do not specify which
measures must be taken for those donors
who were potentially exposed to T. cruzi
infection in the past but who have not yet
been tested. In contrast, a guideline from
the Council of Europe entitled ‘‘Guide to
preparation Use and Quality Assurance of
Blood Components’’ (16th edition) specif-
ically recommends performing a validated
test for T. cruzi infection in donors who
were born or transfused in areas where the
disease is endemic (Table 1). Accordingly,
the EU directive is out of step with the
Council of Europe’s recommendations.
The authors of this paper did not find
any source to determine whether all blood
banks from any country without a specific
national directive or legislation in this
regard are following this recommendation.
Transplantation health policy
We did not find any national directive
or legislation regarding solid organ trans-
plantation that includes Chagas disease as
a specific topic. The EU directive con-
cerning the regulation of solid organ
donations does not specifically address
measures to control T. cruzi infection. It
mentions only that there are particular
conditions that might affect the suitability
of organs for transplantation because they
imply the risk of infectious disease trans-
mission.
Three national transplant organizations
from Italy, Spain, and the United King-
dom have included a specific section
regarding how to control transmission of
Chagas disease through organ transplanta-
Figure 2. Blood transfusion health policy on T. cruzi infection in EU countries and Switzerland.
doi:10.1371/journal.pntd.0003245.g002
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tion in their national guidelines about
quality of safety of solid organ transplants
(Figure 3). Accordingly, transplant donors
in these countries are routinely screened,
although seropositivity for Chagas disease
might not be a contraindication for some
type of transplants. By way of example, in
Spain there is a very clear recommendation
to test for T. cruzi in all donors at risk of
infection; recipients of an organ from a
positive donor are strictly followed up and
monitored for the development of T. cruzi.
Spanish and Latin American experts in
Chagas disease have published recommen-
dations concerning the management of
Chagas disease in transplants [31]. In the
UK, professional guidelines are produced
by the Department of Health’s Advisory
Committee on the Safety of Blood, Tissues
and Organs (SaBTO). The donor patient
assessment form includes questions which
permit an assessment of the donor possibly
harbouring T. cruzi infection to be under-
taken and testing to be performed where
relevant.
The Council of Europe has also elabo-
rated a guideline entitled ‘‘Safety and
Quality assurance for the transplantation
of organ, tissues and cells’’ (4th edition,
2010) (Table 1). This guideline also rec-
ommends testing donors from endemic
areas and specifies criteria for transplant
contraindications.
Information about Germany, France, or
Finland, which recommends following the
Council of Europe’s guidelines, has been
gathered, but the authors of this paper
could not obtain any specific national
document to corroborate this recommen-
dation. To the best of our knowledge, the
rest of the European countries apply EU
or similar directives, but this paper has not
assessed the degree to which the guidelines
of the Council of Europe are applied.
Congenital transmission
European countries have no legislation
requiring screening of pregnant women
coming from Chagas disease–endemic
areas and monitoring their offspring,
except in three autonomous communities
in Spain (Catalonia, Galicia, and Valen-
cia) and one region in Italy (Tuscany)
(Figure 4). In these four regions, a T. cruzi
test must be done as a part of the required
screening tests undertaken during antena-
tal care. When pregnant women test
positive, newborns are tested for congen-
ital Chagas disease and treated early if
found to be infected with T. cruzi or
followed up for at least nine months until
the infection can be reliably ruled out. On
the other hand, nongovernmental pro-
grammes are slowly being implemented in
some other regions of Spain (four auto-
nomic communities), Italy (three regions),
Germany (one state), Portugal (two dis-
tricts), and Switzerland (two cantons)
(Figure 3). In these cases, protocols are
being applied in some hospitals and
maternity units but they cannot be con-
sidered as official recommendations. In the
UK, there is no legislation and currently
no routine antenatal screening programme
Figure 3. Transplantation health policy on T. cruzi infection in EU countries and Switzerland.
doi:10.1371/journal.pntd.0003245.g003
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for Chagas disease. However, the UK
Health Protection Agency (now Public
Health England) Migrant Health Guide
2011 states that pregnant women from at
risk groups should be offered serological
testing, and any positives should be referred
to a specialist centre. Infants of seropositive
mothers should be followed up to detect
and treat any cases of vertical transmission.
In the remaining countries there is no
legislation concerning Chagas disease.
Discussion
Transmission of CD is a real possibility
in countries hosting populations from
Latin American endemic countries
[9,10,18,30]. Some European countries,
particularly those with a large number of
Latin American immigrants, are slowly
acknowledging this growing public health
problem, and some changes in health
policies have been made.
With reference to transmission through
blood transfusion, seven countries have
either already implemented, or are in the
process of, changing their recommenda-
tions to enhance detection of cases of T.
cruzi infection: France, Italy, Portugal,
Spain, Sweden, Switzerland, and the
United Kingdom. These countries have
taken the initiative to change their prac-
tice; they have the highest percentage of
Latin American immigrants and the high-
Table 1. European or national directives, legislations, and guidelines to prevent transmission of Chagas disease.
COUNTRY DIRECTIVE URL YEAR
TRANSFUSSION SPAIN REAL DECRETO 1088/2005 http://www.boe.es/boe/dias/2005/09/20/pdfs/
A31288-31304.pdf
2005
FRANCE Arreˆte´du 12 janvier 2009:
Legifrance, editor. NOR SJSP0901086A
http://www.legifrance.gouv.fr/affichTexte.
do?cidTexte=JORFTEXT000020104647&date
Texte=&categorieLien=id
2009
UNITED KINGDOM Guidelines for the Blood Transfusion
Services In: Services UBTTT. The
Stationery Office (TSO)
https://www.gov.uk/government/uploads/
system/uploads/attachment_data/file/
228828/0117033715.pdf
2005
SWEDEN Socialstyrelsens fo¨reskrifter om
blodverksamhet;
http://www.socialstyrelsen.se/sosfs/2009-28/
Documents/2009_28_rev.pdf
2009
SUIZA Prescriptions du Service de transfusion
sanguine CRS
http://sbsc-bsd.ch/dokuman/Portals/0/kip/
m0/1299/1305/21740-Aptitude-V08__8__8.pdf
2013
EU Commission Directive 2004/33/EC, 2004 http://eur-lex.europa.eu/LexUriServ/LexUriServ.
do?uri=OJ:L:2004:091:0025:0039:EN:PDF
2004
EU Commission Directive 2006/17/EC, 2006 http://eur-lex.europa.eu/LexUriServ/LexUriServ.
do?uri=OJ:L:2006:038:0040:0052:EN:PDF
2006
COUNCIL OF EUROPE Guide to the preparation, use and
quality assurance of blood components.
16th edition 2010
http://tots.edqm.eu/entry.htm
2010
TRANSPLANT EU Directive 2010/45/EU http://eur-lex.europa.eu/LexUriServ/LexUriServ.
do?uri=OJ:L:2010:189:0001:0008:EN:PDF
2010
SPAIN Criterios de seleccio´n del donante de
o´rganos respecto a la transmisio´n de
infecciones
http://www.ont.es/infesp/DocumentosDe
Consenso/infecciondonante.pdf
2004
ITALY Criteri generali per la valutazione di
idoneita` del donatore
http://www.sanfilipponeri.roma.it/trapianti/file/
140812_linee_guida_donatore.pdf
2012
UNITED KINGDOM Guidance on the Microbioolgical
safety of human organ, tissues and
cells used in transplantation. SaBTO
https://www.gov.uk/government/publications/
guidance-on-the-microbiological-safety-of-
human-organs-tissues-and-cells-used-in-
transplantation
2011
COUNCIL OF EUROPE Safety and quality assurance for the
transplantation of organs, tissues
and cells
http://tots.edqm.eu/entry.htm 2010
CONGENITAL SPAIN (Catalonia) Protocol de cribratge i diagno`stic
de malaltia de Chagas en dones
embarassades llatinoamericanes i
en els seus nadons
http://www20.gencat.cat/docs/canalsalut/
Home%20Canal%20Salut/Professionals/
Temes_de_salut/Chagas/documents/
Protocol_cribratge_Chagas_def.pdf
2010
SPAIN (Valencia) Enfermedad de Chagas importada
protocolo de actuacio´n en la
comunitat Valenciana
http://publicaciones.san.gva.es/publicaciones
/documentos/V-5243-2008.pdf
2008
SPAIN (Galicia) protocolo de cribado da enfermidade
de Chagas en mulleres embarazadas
http://www.sergas.es/Publicaciones/
DetallePublicacion.aspx?IdPaxina=60020&
Idioma=es&IDCatalogo=2215
2012
ITALY (Toscana) Prevenzione e controllo della malattia
di Chagas congenita: indicazioni per
l’assistenza in gravidanza
http://parlamentosalute.osservatorioistituzioni.
it/system/attachments/assets/000/007/568/
original/489a.pdf
2012
doi:10.1371/journal.pntd.0003245.t001
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est risk of transmitting the disease. In
Sweden, where systematic screening has
not been implemented in blood banks, but
all individuals who lived more than five
years in Chagas disease–endemic countries
are systematically excluded from donation,
the risk of disease transmission through
transfusion is substantially reduced, but
gaps remain in this regulation such as in
the case of donors whose mothers were
born in endemic areas. For the rest of the
European countries, the official directives
either exclude donations only in patients
confirmed to be infected, or do not apply
any measure. The problem is that the
majority of chronically infected people
either do not show any symptoms or have
symptoms that simulate other conditions;
therefore, the possibility of CD might not
be suspected. When such people are not
screened, there is a potential risk of
transmission of T. cruzi infection in those
countries. Furthermore, because of the
particularities of CD, a deferral period in
blood donation six months after the
migrant process or after the last trip,
which is often applied, does not give any
protection against transmission of Chagas
disease in transfusional practice.
A European guideline recommends
screening all people at risk of Chagas
disease, but we do not know if national
blood banks are applying it since the
extent to which it has been implemented
has not been assessed. Even though the
total number of Latin American immi-
grants in these countries is low compared
to the seven countries mentioned, poten-
tial transmission of Chagas disease is a
public health concern. This problem
might become more relevant in the
context of the recent economic crisis given
the unpredictable internal migration flows
within European countries. It must also
be considered that some of these immi-
grants might have received a European
nationality at the time of their re-migra-
tion, making it more difficult to identify
individuals at risk of the infection.
With regards to health policies for solid
organ transplantation, no country has a
specific directive or legislation that consid-
ers Chagas disease in all patients at risk.
Even the EU directives do not specifically
mention T. cruzi infection as a potential
risk for recipients of solid organ trans-
plants. In such cases, the severity of the
disease is potentially more important
because these patients will be permanently
immunosuppressed.
Although the Council of Europe guide-
line mentions Chagas disease risk and is
theoretically followed by some European
countries, we do not know if testing has
been systematically implemented by na-
tional transplant programmes. To our
knowledge, only three countries (Italy,
Spain, and the United Kingdom) have
national guidelines to control this route of
Figure 4. Control of congenital transmission of T. cruzi infection in EU countries and Switzerland.
doi:10.1371/journal.pntd.0003245.g004
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transmission through systematic screening
in all donors at risk of the infection. The
outlook is even less promising concerning
the congenital transmission route. Only
four first administrative divisions (FAD)
among countries considered have imple-
mented adequate policies to test newborns
at risk of the infection. As far as we know,
the rest of FAD and other countries have
not any protocols or directives with the
exception of some non-official local initia-
tives in some FAD. Control of congenital
transmission has been demonstrated to be
one of the most cost-effective measures to
control the disease [26]. Since newborns
with acute disease can be cured easily if
diagnosed and treated early, subsequent
cardiac, digestive, and neurological com-
plications might be prevented in a signifi-
cant percentage of affected people, and the
possibility of further transmission to subse-
quent generations will also be avoided.
This study has several limitations. First,
other non-official initiatives to control the
transmission of the infection might exist
but we could not find them. Moreover, in
countries where a directive already exists,
we have not evaluated the correct imple-
mentation of the directive or policy. Thus,
we cannot be sure that the transmission of
the infection is avoided. Finally, not all
European countries were included in the
study; however we should also consider
that most Latin American immigrants in
Europe are living in the European coun-
tries that were described in our study.
Conclusions and
Recommendations
To ensure control of Chagas disease
transmission in European countries,
changes in some laws and directives
concerning blood banks and transplant
programmes are urgently needed to avoid
or reduce the risk of transmission. It would
be useful that regulations emanating from
the European Commission were in accor-
dance with the recommendations from
the Council of Europe. In addition, in
countries where legislation exists, efforts
should be made to evaluate the imple-
mentation of these directives in blood
banks to apply adequate systematic screen-
ing of all people at risk of T. cruzi infection
with a validated method, incorporating
internal and external quality controls of
the serological test. Finally, programmes to
control congenital Chagas disease should
be implemented in all European countries
based on the screening of pregnant women
at risk of the infection, with the primary
objective of treating infected newborns at
an early stage.
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